Summarized by Masters of Longevity from Peter Attia Blog.
Myostatin inhibitors: a science feature explaining why drugs that enlarge muscle often don’t translate to stronger, functional gains.
Key Takeaways
- Apitegromab added to tirzepatide reduced lean mass loss to 1.6 kg versus 3.5 kg with placebo over 24 weeks.
- Despite retaining more lean mass, the apitegromab group showed no statistically significant strength advantage versus placebo.
- Prior myostatin blocker trials like bimagrumab increased muscle volume but did not reliably improve functional strength in older adults.
